State of Michigan Retirement System bought a new stake in shares of Novo Nordisk A/S (NYSE:NVO – Free Report) in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 200,000 shares of the company’s stock, valued at approximately $25,680,000.
Other institutional investors have also modified their holdings of the company. Pacific Center for Financial Services raised its position in Novo Nordisk A/S by 100.0% during the third quarter. Pacific Center for Financial Services now owns 270 shares of the company’s stock valued at $25,000 after acquiring an additional 135 shares in the last quarter. First PREMIER Bank acquired a new position in shares of Novo Nordisk A/S in the 1st quarter valued at $25,000. CNB Bank purchased a new stake in Novo Nordisk A/S during the fourth quarter worth $26,000. West Paces Advisors Inc. increased its holdings in Novo Nordisk A/S by 100.0% in the third quarter. West Paces Advisors Inc. now owns 300 shares of the company’s stock valued at $27,000 after buying an additional 150 shares in the last quarter. Finally, Valued Wealth Advisors LLC acquired a new position in shares of Novo Nordisk A/S in the fourth quarter worth about $28,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.
Novo Nordisk A/S Trading Down 1.7 %
Shares of Novo Nordisk A/S stock opened at $143.00 on Wednesday. Novo Nordisk A/S has a 1-year low of $75.56 and a 1-year high of $148.15. The company has a debt-to-equity ratio of 0.17, a current ratio of 0.70 and a quick ratio of 0.50. The stock has a market cap of $641.72 billion, a P/E ratio of 49.31, a P/E/G ratio of 1.42 and a beta of 0.41. The stock’s 50 day simple moving average is $135.40 and its 200-day simple moving average is $124.04.
Wall Street Analyst Weigh In
NVO has been the subject of several recent analyst reports. BMO Capital Markets restated an “outperform” rating and issued a $163.00 price target on shares of Novo Nordisk A/S in a research note on Tuesday, June 25th. Argus boosted their price objective on Novo Nordisk A/S from $125.00 to $160.00 and gave the company a “buy” rating in a research report on Monday, June 10th. The Goldman Sachs Group assumed coverage on Novo Nordisk A/S in a research note on Thursday, May 30th. They set a “buy” rating and a $156.00 target price for the company. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research note on Monday. Two equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $145.67.
Novo Nordisk A/S Profile
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.
Featured Stories
- Five stocks we like better than Novo Nordisk A/S
- Top Stocks Investing in 5G Technology
- Generac Holdings Stock: Mixed Signals Leave Investors Uncertain
- What is a SEC Filing?
- Analysts and Earnings Propel the S&P 500’s Continuous Growth
- Pros And Cons Of Monthly Dividend Stocks
- CrowdStrike Stock Soars, Outpacing Palo Alto in Cybersecurity
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.